Use of n-3 PUFAs can decrease the mortality in patients with systemic inflammatory response syndrome: a systematic review and meta-analysis

Xiao Wan¹, Xuejin Gao², Jingcheng Bi¹, Feng Tian¹ and Xinying Wang¹*

Abstract

Background: There have been several meta-analyses evaluating the effect of n-3 polyunsaturated fatty acids (PUFAs) in critically ill patients, but of these, none focused on patients with systemic inflammatory response syndrome (SIRS). The objective of this meta-analysis was to evaluate the effect of omega-3 fatty acids (n-3 FAs) on this narrow subset.

Methods: All relevant articles were searched on MEDLINE, EMBASE, SpringerLink, and the Cochrane Database of Systematic Reviews from 1990 to 2014. Meta-analyses were used to evaluate risk ratios and mean differences with 95% confidence intervals between the n-3 PUFA group and the control group. Subgroup analyses were conducted in terms of the route of fish oil.

Results: Nine randomized controlled trials (RCTs) with 783 adult patients were included in this study. Compared with control groups, n-3 FA provision can significantly reduce the incidence of mortality (RR: 0.77 [0.60, 0.97]; P = 0.03; I² = 0%). Secondary outcomes showed no significant differences between groups except for shorter length of hospital stay (weighted mean difference: −10.56 [−19.76, −1.36], p < 0.00001, I² = 99%).

Conclusions: Overall, this meta-analysis from RCTs indicates that provision of n-3 PUFAs has a therapeutic effect on survival rate in patients with SIRS.

Keywords: Polyunsaturated fatty acids, Sepsis, SIRS, Mortality, Outcome

Introduction

Systemic inflammatory response syndrome (SIRS) is an inflammatory state affecting the whole body. Frequently, it is the result of the body’s immune response to an infectious or noninfectious insult [1-3]. It is related to sepsis, a condition in which individuals meet criteria and have a known infection. SIRS is characterized by systemic inflammation, organ dysfunction, and organ failure such as acute lung injury, acute kidney injury, shock, and multiple organ dysfunction syndrome. Although antibiotics and various supportive therapies are constantly being developed, it remains one of the major causes of death in critically ill patients [3]. Thus, learning how to effectively control the body’s systemic inflammation is an important research target for the treatment of SIRS.

Omega-3 polyunsaturated fatty acids (n-3 PUFAs) are essential fatty acids and are considered as providing potential health benefits [4,5]. Supplementation with n-3 PUFAs, either parenterally or enterally, is thought to be potentially beneficial in modulating inflammatory processes [6]. In 2009, the European Society for Parenteral and Enteral Nutrition (ESPEN) guidelines recommended the use of fish oil in critical patients, especially in those with acute lung injury, sepsis, or SIRS [7]. However, in the OMEGA trial, the therapeutic effect on acute lung injury disappeared [8], making the use of n-3 fish oil a topic of controversy [9].

Recently, many randomized controlled trials (RCTs) have investigated the effect and safety of fish oil on SIRS or sepsis [10-18]. However, interpretation of these results is problematic owing to the small sample sizes and
methodic limitations. Moreover, several recent RCTs reported conflicting data. As a result of the advantages and disadvantages of n-3 PUFAs, we performed a systematic review of RCTs with meta-analysis to investigate the effect of n-3 PUFA supplementation in adult patients with SIRS or sepsis.

Results
Study selection and risk of bias
A total of 192 potentially relevant studies were retrieved, and six additional records were identified through other sources. The process of selecting relevant trials is described in Figure 1. Finally, nine citations of RCTs with a total of 783 patients were included in our meta-analysis [10-18]. Among these trials, two were conducted in Spain, two in Brazil, and one each in Portugal, Germany, United States, Egypt, and Taiwan. In four trials, fish oil was administered intravenously, while in the others, it was administered enterally. The characteristics of the included trials are shown in Table 1.

Among the selected trials, four were double blind, three were single blind, and two were open-label trials. All the risks of bias item for each included study were presented in Figures 2 and 3. Randomized sequence and allocation sequence concealment were conducted adequately, except for the 2013 trial [16]. One trial was evaluated as having a high risk of reporting bias because of the lack of morbidity [17].

Clinical outcomes
The results of the meta-analysis are demonstrated in Table 2. The primary meta-analysis outcome of eight trials with 706 participants was that the use of n-3 PUFAs significantly reduced mortality in patients with SIRS, as shown in Figure 4 (RR: 0.77 [0.60, 0.97]; P = 0.03; I² = 0%). The funnel plot is presented in Figure 5.

Besides, with the limitation in Pontes-Arruda, et al. [17] that several deceased patients were assigned into the “withdrew” group, we reanalyzed in terms of an assumption that the patients who were still alive when they were withdrawn from the study have the same mortality as the patients continuing in Pontes-Arruda, et al. [17]. The death rates were 63/103 in the control group and 43/104 in the fish oil group, respectively. The result was the same as before: n-3 PUFAs significantly reduced mortality in patients with SIRS (RR: 0.64 [0.46, 0.87]; P = 0.005; I² = 0%) (Figure 6).

When we evaluated secondary outcomes including days on ventilation, ventilator-free days, LOS-ICU, and LOS-H, the heterogeneity was significant. The n-3 FA had therapeutic effects in fixed models: days on ventilation (WMD: −3.57 [−4.22, −2.91], P < 0.00001, I² = 95%), ventilator-free days (WMD: 7.29 [6.88, 7.71], p < 0.00001, I² = 96%), LOS-ICU (WMD: −2.76 [−3.42, −2.10], P < 0.00001, I² = 92%), LOS-H (WMD: −5.04 [−5.86, −4.22], P < 0.00001, I² = 99%). However, these effects were no longer present in a random effects model except for shortening the LOS-H: days on ventilation (WMD: −2.61 [6.29,1.07], P = 0.17, I² = 95%), ventilator-free days (WMD: 3.09 [−3.34,9.51], P = 0.35, I² = 96%), LOS-ICU (WMD: −1.35 [−4.12, 1.43], P = 0.34, I² = 92%), and LOS-H (WMD: −10.56 [−19.76, −1.36], P < 0.02, I² = 99%). All the results in random effects models are presented in Figures 7, 8, 9 and 10.
| Author/year   | Blind       | Intervention                                      | n-3/n-6 ratio | Dose and form of fish oil                  | Route   | No. of patients (valued/enrolled) | Days | Severity of illness | Mortality                                      |
|--------------|-------------|---------------------------------------------------|---------------|------------------------------------------|---------|-----------------------------------|------|---------------------|-----------------------------------------------|
| Barbosa 2011 | Single-blind| FO + LCT + MCT vs. LCT + MCT                        | FO group 1:4  | Dose: not mentioned Form: 2.5% EPA 1.1% DHA | Parenteral | 23/25                            | 5    | SAPS II: 47.5 ± 5 vs. 41.6 ± 6.5             | 28-day mortality: 4/13 vs. 4/10                  |
| Cristóbal 2000 | Single-blind | Impact. vs. control                                | Not reported  | Not mentioned                            | Enteral | 176/181                          | 24   | APACHE II: 18.4 ± 5.6 vs. 17.9 ± 5.2         | Hospital mortality: 17/89 vs. 28/87              |
| Friescke 2008 | Double-blind | FO + LCT + MCT vs. LCT + MCT                        | FO group 1:2  | Dose: not mentioned Form: 2.5% EPA 0.08%GLA | Parenteral | 80/114                           | 7    | SAPS II: 49 ± 18 vs. 54 ± 17                 | 28-day mortality: 10/42 vs. 8/38                 |
| Grau-Carmona 2011 | Single-blind | EPA + GLA vs. control                              | FO group 1: 1.5 | Dose: not mentioned Form: 2.5% EPA 1.1% DHA | Enteral | 132/160                          | 7–22 | SOFA: 9 (7–11) vs. 9 (8–11) a APACHE II: 19 (16–24) vs. 19 (16–23) a | 28-day mortality: 11/61 vs. 11/71                  |
| Hall 2014     | No-blind    | FO + stand care vs. stand care                     | Not mentioned (Omegaven was used singly in FO group) | Dose: 0.2 g/kg/d Form: 1.25%–2.82% EPA 1.44%–3.09% GLA | Parenteral | 60/87                            | ≤14  | APACHE II: 19.1 ± 6.7 vs. 17.9 ± 6.2 SOFA: 7.2 ± 3.0 vs. 7.6 ± 3.2 | Hospital mortality: 4/30 vs. 9/34                  |
| Hosny 2013    | Not mention | high dose FO vs. low dose FO vs. control           | high FO group 1.6 low FO group 1:20 | Dose: high FA 9 g/d low FA 3 g/d control 0 Form: not mentioned | Enteral | 75/not reported | 7    | SOFA: 3.7 ± 0.96 vs. 3.3 ± 1.31 vs. 3.6 ± 0.87 | 28-day mortality: 8/25 vs.11/25 vs. 10/25         |
| Khor 2011     | Double-blind | FO vs. placebo                                     | Not mentioned (Omegaven® was used singly in FO group) | Dose: 10 g/d Form: 1.25%–2.82% EPA 1.44%–3.09% GLA | Parenteral | 27/28                            | 5    | APACHE II: 19.3 ± 7.8 vs. 16.3 ± 7.2 SAPS II: 52.9 ± 22.5 vs. 48.4 ± 15.1 | 28-day mortality: 0/14 vs. 0/13                  |
| Pontes-Arruda 2006 | Double-blind | EPA + GLA vs. control                              | FO group 1:1.85 control group 1:3.8 | Dose: not mentioned Form: 4.5% EPA 4.3% GLA 2% DHA | Enteral | 103/165                          | 4–7  | SOFA: 8.8 ± 0.9 vs. 8.6 ± 0.8               | 28-day mortality: 18/55 vs. 25/48                |
| Pontes-Arruda 2011 | Double-blind | EPA + GLA vs. control                              | FO group 1:1.85 control group 1:3.8 | Dose: not mentioned Form: 4.5% EPA 4.3% GLA 2% DHA | Enteral | 53 vs. 53                         | 7    | APACHE II: 19.5 (17–25) vs. 20 (16–23) a SOFA: 5.5 (4–9) vs. 6 (4–8) a | Not reported                                    |

Values are presented as mean ± standard deviation unless indicated otherwise.

a – median (interquartile range), APACHE – acute physiology and chronic health evaluation, DHA – docosahexaenoic acid, EPA – eicosapentaenoic acid, FO – fish oil, GLA – gamma-linolenic acid, LCT – long chain triglycerides.

MCT – medium chain triglycerides, SAPS – simplified acute physiology score, SOFA – Sequential organ failure assessment.
Subgroup analysis

A subgroup analysis was performed to compare the difference between parenteral and enteral routes, but no difference was observed for mortality (P = 0.84, I² = 0%), days on ventilation (P = 0.46, I² = 0%), LOS-ICU (P = 0.27, I² = 18.6%) and LOS-H (P = 0.81, I² = 0%). By contrast, the difference for ventilator-free days was significant (P = 0.0003, I² = 92.4%), which was likely to be caused by the small sample size (n = 4).

Discussion

According to the RCT meta-analysis, n-3 PUFA supplementation has a therapeutic effect on patients with sepsis or SIRS because it can effectively reduce mortality without heterogeneity. It also can shorten the LOS-H. However, the n-3 FA group does not statistically differ from placebo or control subjects in terms of days on ventilation, ventilator-free days, and LOS-ICU. Significant heterogeneity among these trials precluded the pooling of results.

Although the anti-inflammatory function of n-3 PUFAs is not known to be associated with the route of supplementation, we performed a subgroup analysis. This result is consistent with the consensus in terms of mortality, days on ventilation, ventilator-free days, LOS-ICU, and LOS-H. The only difference that is not as reliable is that of ventilator-free days, because of its small sample size and contradiction with days on ventilation.

It is crucial that, in the provision of nutrition support, strategies should be adopted to optimize benefit and minimize potential harm. Recently, immunonutrition has been extensively applied in clinical practice, especially with respect to n-3 FAs in critically ill patients. Fish oil intake, which provides eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), results in a higher proportion of EPA and DHA in the cell membrane, thereby decreasing the synthesis of inflammatory cytokines such as tumor necrosis factor-alpha, interleukin-6, and interleukin-8 [19,20].
Early studies confirmed that fish oil can reduce the mortality of critically ill patients with acute lung injury (ALI), sepsis, and SIRS [12,18]. A decrease in length of stay without any other detectable effects has also been shown in surgical patients requiring intensive care after five days of n-3 FA emulsion [21]. Fish oil use in patients with severe pancreatitis also resulted in decreased inflammatory response, as well as improved respiratory function [22,23]. Friesecke et al. revealed an opposing opinion, reporting that use of a mixed long-chain triglyceride (LCT)/medium-chain triglyceride (MCT)/fish oil lipid emulsion in critically ill ICU patients had no improvement on clinical outcomes including infections, ventilation days, LOS-ICU, or LOS-H compared with MCT/LCT. In fact, the ESPEN guidelines show a Grade B recommendation for the infusion of fish oil in critically ill patients [7,13].

In recent years, some studies have yielded different results, especially the OMEGA study. This study for fish oil in the treatment of patients with ALI has subversive significance. The two articles about n-3 PUFAs in patients with ALI/acute respiratory distress syndrome (ARDS) also point out that if the OMEGA study were included, the heterogeneity of the research would be obvious ($I^2 = 31\%$), and the beneficial effect of fish oil for the treatment of patients would have no clinical significance ($P = 0.36$) [9]. If the OMEGA study were excluded, however, the heterogeneity would disappear ($I^2 = 0\%$), and we would be able to positively confirm that fish oil does reduce mortality, accompanied by a decline in reliability [24]. The two authors made different choices, which resulted in two opposite sets of conclusions and recommendations.

In addition, the use of fish oil may affect clinical outcomes, although the traditional view has been that oral and intravenous fish oil only differ in effect speed and utilization degree. A meta-analysis in 2014 confirmed that parenteral fish oil had a tendency to reduce the mortality of ICU patients without heterogeneity ($P = 0.08$) [25]. After we compared the result with the investigation conclusions for ALI/ARDS, concerns were raised as to whether the use of methods (enteral vs. parenteral) and disease type (ALI/ARDS vs. sepsis/SIRS) had a large influence on response to treatment.

### Table 2 Meta-analysis of included trials

| Outcome of interest | No. of trials | No. of patients | Fixed effect model | Random effects model |
|---------------------|---------------|-----------------|--------------------|---------------------|
|                     |               |                 | RR/WMD (95% CI) P  | RR/WMD (95% CI) P   |
|                     |               |                 | I²                  | I²                  |
| Mortality           | 8             | 706             | 0.77 [0.60, 0.97] 0.03 | -                   |
| Days on ventilation | 6             | 567             | -3.57 [-4.22, -2.91] <0.0001 95% | -2.61 [-6.29, 1.07] 0.17 95% |
| Ventilator-free days| 3             | 243             | 7.29 [6.88, 7.71] <0.0001 96% | 3.09 [-3.34, 9.51] 0.35 96% |
| LOS-ICU             | 8             | 656             | -2.76 [-3.42, -2.10] <0.0001 92% | -1.35 [-4.12, 1.43] 0.34 92% |
| LOS-H               | 4             | 217             | -5.04 [-5.86, -4.22] <0.0001 99% | -10.56 [-19.76, -1.36] 0.02 99% |

LOS-H – length of stay in hospital, LOS-ICU – length of stay in intensive care unit, RR – relative risk, WMD – weighted mean difference.

### Figure 4

Forest plot of comparison: Effect of n-3 fish oil supplementation on mortality. CI – confidence interval, RR – relative risk.
Our meta-analysis answered this question. It indicated that mortality was significantly reduced by the n-3 FA supplementation, which was in line with the result of Marik et al. [26]. There are, however, several possible explanations for the former question. First, n-3 FA can effectively suppress systemic inflammation. Second, there is no significant difference between the parenteral and enteral groups, which proves that the method of use does not influence the anti-inflammatory effects of fish oil. In addition, the parenteral fish oil in the total group cannot obviously improve mortality, and this significant result is probably a false negative result because the number of people enrolled is small (n = 195) [27]. We need more clinical research detailing parenteral n-3 FA in patients with sepsis or SIRS to confirm this conclusion.

However, some limitations of this meta-analysis should be considered. First, all the trials included in this study are small sample clinical trials, and the biggest single study enrolled only 176 participants. Even though the funnel plot figure of mortality confirmed equal research distribution without obvious bias, the credibility of the results still needs to be considered with caution, and we need more large sample clinical studies to solve this problem. Second, the other results have

---

**Figure 5** Funnel plot of comparison: Effect of n-3 fish oil supplementation on mortality. RR – relative risk.

**Figure 6** Forest plot of comparison: Effect of n-3 fish oil supplementation on assumed total mortality. CI – confidence interval, RR – relative risk.
high heterogeneity. After using subgroup analysis in terms of intervention or illness severity, we failed to find the source of heterogeneity. It’s likely that the included trials differed in nutrition formula, administration, and treatment protocol. Moreover, the primary cause of SIRS is various, and most of trials reported multiple causes. Thus, caution should be taken when interpreting the results, and high heterogeneity greatly reduces the credibility of these conclusions.

Conclusions
In conclusion, when nutrition is prepared for patients with sepsis or SIRS, supplemental n-3 PUFAs is associated with lower mortality, and, if possible, should be considered the standard choice for nutritional support. It also has the potential ability to shorten the LOS-H. Future large-scale, high-quality RCTs are still required to clarify the effectiveness of n-3 FA supplementation in sepsis and SIRS, especially by the intravenous route.

Methods
Study Identification
Two researchers independently searched the published literature without language restrictions using the keywords “omega-3 fatty acids,” “fish oils,” “sepsis,” “SIRS,” “critical illness,” and their analogues on MEDLINE, EMBASE, SpringerLink, and the Cochrane Database of Systematic Reviews from 1990 to 2014. Potentially relevant studies from the identified reports were searched to find relevant trials. Abstracts from scientific meetings were accepted in the review if the data were available to complete the analysis.

Inclusion and Exclusion Criteria
Original studies were selected for inclusion in the review process only if they met the following conditions: (1) the study design was consistent with clinical RCTs; (2) the study population comprised patients > 14 years of age who were diagnosed with sepsis or SIRS; (3) the intervention
was fish oil (enteral, parenteral, or both) versus control (other lipid or placebo); and (4) clinical outcomes were pre-specified, including one of the following: mortality, days on ventilation, ventilator-free days, length of stay in intensive care unit (LOS-ICU), and in hospital (LOS-H). Studies that evaluated only biochemical, metabolic, immunologic, or nutritional outcomes were not included. Furthermore, if n-3 PUFAs were administered for less than 24 hours, the article was to be excluded.

Data extraction
All original studies were retrieved in duplicate by two independent reviewers (Wan Xiao and Gao Xuejin), using a data abstraction form. The following data were extracted from each study: authors, year of publication, study design, patient characteristics, study methodology (e.g., inclusion/exclusion criteria, nutrition administration protocol, randomization, and blinding), intervention (e.g., duration, form, and daily dose), and outcome measures. We attempted to contact the authors of included studies and requested additional information not contained in published articles.

Assessment of risk bias
All original data were evaluated independently by two reviewers. The risk bias of included trials was assessed using the components recommended by the Cochrane Collaboration: random sequence generation; allocation concealment; blinding of participants, personnel, and outcome assessors; incomplete outcome data; selective reporting; and other sources of bias [28]. Disagreement on the individual risk bias of each of the categories was resolved by consensus between both reviewers.

Statistical analysis
The analyses were performed in RevMan 5.2 (The Nordic Cochrane Centre, Copenhagen, Denmark). As part of the results were abnormally distributed, we represented the
data as mean ± SD [29]. If hospital mortality was not reported, we used 28-day or 60-day mortality instead. The differences between the fish oil group and control group were expressed by the relative risk (RR) and the weighted mean difference (WMD) with 95% confidence intervals (CI) for dichotomous and continuous outcomes, respectively. The presence of heterogeneity was quantified using the I² statistic. If without statistical heterogeneity (I² = 0%), a fixed-effect model was used; otherwise, both fixed-effect model and random effects models were used [30]. Graphic exploration with a funnel plot was used to visually evaluate the small trial bias.

Abbreviations
CI: Confidence interval; n-3 PUFAs: Omega-3 polyunsaturated fatty acids; SIRS: Systemic inflammatory response syndrome; ESPEN: the European Society for Parenteral and Enteral Nutrition; RCT: Randomized controlled trials; LOS-E-U: Length of stay in intensive care unit; LOS-H: length of stay in hospital; RR: Relative risk; WMD: Weighted mean difference; EPA: Eicosapentaenoic acid; DHA: Docosahexaenoic acid; LCT: Long-chain triglyceride; MCT: Medium-chain triglyceride; ARDS: Acute respiratory distress syndrome.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
XW, XG, JB, FT and XW designed the study. XW, XG, JB, FT searched the data and analyzed the data. XW, XG and JB drafted the manuscript, and XW reviewed the manuscript. All authors read and approved the manuscript.

Acknowledgements
The data for this analysis were analyzed with the assistance of Dr. Chao Wu and Dr. Li Zhang.

Author details
1Department of General Surgery, Jinling Hospital, School of Medicine, Nanjing University, Nanjing, Jiangsu Province, China. 2Clinical College of South Medical University, Guangdong Province, China.

Received: 12 November 2014 Accepted: 19 March 2015 Published online: 31 March 2015

References
1. Anneke D, Bellissant E, Cavillon JM. Septic shock. Lancet. 2005;365:63–78.
2. Investigators PCESS, Yealy DM, Kellum JA, Huang DT, Barnato AE, Weissfeld LA, et al. A randomized trial of protocol-based care for early septic shock. N Engl J Med. 2014;370:1683–93.
3. Angus DC, van der Poll T. Severe sepsis and septic shock. N Engl J Med. 2013;369:840–51.
4. Waiczberg DL, Tontios RH. Fish oil lipid emulsions and immune response: what clinicians need to know. Nutr Clin Pract. 2009;24:487–99.
5. Okamoto Y, Okano K, Ishiki K, Usuki H, Wakabayashi H, Suzuki Y. Attenuation of the systemic inflammatory response and infectious complications after gastrectomy with preoperative oral arginine and omega-3 fatty acids supplemented immunonutrition. World J Surg. 2009;33:1815–21.
6. Olland E, Hossain MB, Khan S, Memon MA. Effect of timing of pharmaco nutrition (immunonutrition) administration on outcomes of elective surgery for gastrointestinal malignancies: a systematic review and meta-analysis. J Parenter Enter Nutr. 2014;38:53–69.
7. Singer P, Berger MM, Van den Bergh G, Brioni G, Calder P, Forbes A, et al. ESPEN guidelines on parenteral nutrition: intensive care. Clin Nutr. 2009;28:387–403.
8. Rice TW, Wheeler AP, Thompson BT, de losblanc BL, Steingrub J, Rock P. Enteral omega-3 fatty acid, gamma-linolenic acid, and antioxidant supplementation in acute lung injury. JAMA. 2011;306:1574–81.
9. Zhu D, Zhang Y, Li S, Gan L, Feng H, Nie W. Enteral omega-3 fatty acid supplementation in adult patients with acute respiratory distress syndrome: a systematic review of randomized controlled trials with meta-analysis and trial sequential analysis. Intensive Care Med. 2014;40:504–12.
10. Barbosa VM, Miles EA, Caluha C, Lafuente E, Calder PC. Effects of a fish oil containing lipid emulsion on plasma phospholipid fatty acids, inflammatory markers, and clinical outcomes in septic patients: a randomized, controlled clinical trial. Crit Care. 2010;14:R5.
11. Bálan C, Montejo JC, Mesejo A, Marco P, Celaya S, Sanchez-Segura JM, et al. An immune-enhancing enteral diet reduces mortality rate and episodes of bacteremia in septic intensive care unit patients. Crit Care. 2000;28:643–8.
12. Frieselke S, Lotze C, Köhler J, Heinrich A, Felix SB, Abel P. Fish oil supplementation in the parenteral nutrition of critically ill medical patients: a randomized controlled trial. Intensive Care Med. 2008;34:1411–20.
13. Grau-Carmona T, Morán-García V, García-de-Lorenzo A, Heras-de-la-Calle G, Quesada-Belver B, López-Martínez J, et al. Effect of an enteral diet enriched with eicosapentaenoic acid, gamma-linolenic acid and anti-oxidants on the outcome of mechanically ventilated, critically ill, septic patients. Clin Nutr. 2011;30:578–94.
14. Hall TC, Bilko DK, Al-Leswas D, Neal CP, Horst C, Cooke J, et al. A randomized controlled trial investigating the effects of parenteral fish oil on survival outcomes in critically ill patients with sepsis: a pilot study. JPEN J Parenter Enteral Nutr. 2014.
15. Hosny M, Nahas R, Ali S, ElHafai SE, Khaled H. Impact of oral omega-3 fatty acids supplementation in early sepsis on clinical outcome and immunomodulation. Egyptian J Critical Care Med. 2013;11:19–26.
16. Khor BS, Liao SJ, Shih HC, Wang LS. Randomized, double blind, placebo-controlled trial of fish-oil-based lipid emulsion infusion for treatment of critically ill patients with severe sepsis. Asian J Surg. 2011;34:1–10.
17. Pontes-Arruda A, Araújo AM, Albuquerque JD. Effects of enteral feeding with eicosapentaenoic acid, gamma-linolenic acid, and antioxidants in mechanically ventilated patients with severe sepsis and septic shock. Crit Care Med. 2006;34:2325–33.
18. Pontes-Arruda A, Martins LF, de Lima SM, Iloa AM, Toledo D, Rezende E, et al. Enteral nutrition with eicosapentaenoic acid, γ-linolenic acid and antioxidants in the early treatment of sepsis: results from a multicenter, prospective, randomized, double-blind study. Crit Care Med. 2008;34:2325–33.
19. Mayer K, Fegbeutel C, Hattar K, Sibelius U, Krämer HJ, Heuer KU, et al. Omega-3 vs. omega-6 lipid emulsions exert differential influence on neutrophils in septic shock patients: impact on plasma fatty acids and lipid mediator generation. Intensive Care Med. 2003;29:1472–81.
20. Singer P, Shapiro H, Theilla M, Anbar R, Singer J, Cohen J. Anti-inflammatory properties of omega-3 fatty acids in critical illness: novel mechanisms and an integrative perspective. Intensive Care Med. 2008;34:1590–92.
21. Wichmann MW, Thul P, Czemetski HD, Morion BJ, Kemen M, Jauch KW. Evaluation of clinical safety and beneficial effects of a fish oil containing lipid emulsion (Lipomuls MLSF41): data from a prospective randomized multicenter trial. Crit Care Med. 2007;35:700–6.
22. Mayer K, Seeger W. Fish oil-containing lipid emulsions in patients with sepsis. Crit Care. 2010;14:128.
23. Wang X, Li W, Zhang F, Pan L, Li N, Li J. Fish oil-supplemented parenteral nutrition in severe acute pancreatitis patients and effects on immune function and infectious risk: a randomized controlled trial. Inflammation. 2009;32:304–9.
24. Manzaare N, Dhalia R, Jurewitz B, Stapledon RD, Jeejeebooy KN, Hayland DK. Parenteral fish oil lipid emulsions in the critically ill: a systematic review and meta-analysis. JPEN J Parenter Enteral Nutr. 2014;38:20–8.
25. Glenn JD, Wschmeyer PE. Enteral fish oil in critical illness: perspectives and systematic review. Curr Opin Clin Nutr Metab Care. 2014;17:116–23.
26. Marik PE, Zaloga GP. Immunonutrition in critically ill patients: a systematic review and analysis of the literature. Intensive Care Med. 2008;34:1980–90.
27. Gani O, Buyse M, Gasride R, Pavey T, Stein K, Sterne JA, et al. Comparison of treatment effect sizes associated with surrogate and final Patient relevant outcomes in randomized controlled trials: meta-epidemiological study. BMJ. 2013;346:f5457.
28. Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions. Chichester: Wiley-Blackwell; 2008.
29. Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol. 2005;5:13.
30. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–58.